Avalyn Pharma Inc. director and officer Lyn Baranowski filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 210,000 shares of common stock under a Rule 10b5-1 plan.
Key Highlights
- Proposed sale size: 210,000 shares of Avalyn Pharma common stock with an aggregate market value of $6,249,600.00.
- Source of shares: The securities are to be received upon the exercise of stock options, acquired from the issuer on November 17, 2026, with cash payment.
- Shares outstanding: According to the filing, 44,521,494 shares of common stock were outstanding at the time of notice.
- 10b5-1 plan: The filing indicates a Rule 10b5-1 trading plan was adopted on July 30, 2026.
- Broker: Sales are to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
- Prior sales: The filing reports nothing to report for securities sold during the past three months.
Baranowski's Proposed Rule 144 Sale at Avalyn Pharma
Avalyn Pharma Inc. (NASDAQ:AVLN), headquartered at 105 W First Street, Boston, Massachusetts, is the issuer named in the Form 144 notice filed on November 17, 2026. The filer, Lyn Baranowski, is identified in the filing as both a director and an officer of the company. The notice covers a proposed sale of 210,000 shares of common stock, with an approximate sale date of November 17, 2026, and an aggregate market value of $6,249,600.00 as stated in the filing.
According to the filing, the shares to be sold were and will be acquired through the exercise of stock options granted by the issuer. The filing notes that "the securities to be sold were and will be received upon the exercise of stock options over the next three months" and that "the dates of acquisition and payment were and will be the dates of exercise/sale." Payment is described as cash. No prior sales during the past three months by Baranowski were reported in the filing.
The filing discloses that Baranowski is relying on a Rule 10b5-1 trading plan, with a plan adoption date of July 30, 2026. By submitting the notice, the filing states that Baranowski represents having no knowledge of any material adverse information regarding the issuer's current and prospective operations that has not been publicly disclosed, as of the plan adoption date.
What Was Disclosed
Lyn Baranowski, a director and officer of Avalyn Pharma Inc., filed a Form 144 notice proposing the sale of 210,000 common shares valued at $6,249,600.00, to be sourced from stock option exercises, under a 10b5-1 plan adopted July 30, 2026.




Please wait processing your request...